Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.57 |
| ▸ | TDO2 | P48775 | 3/20 | 0.55 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144907 | 0.76 | PNMT (0.46) | IDO1TDO2PNMTOPRL1OPRM1 | |
| SCHEMBL4157268 | 0.76 | PNMT (0.58) | IDO1TDO2PNMTOPRL1OPRM1 | |
| SCHEMBL27331494 | 0.74 | IDO1 (1.00) | IDO1 | |
| SCHEMBL8410943 | 0.73 | IDO1 (0.61) | IDO1TDO2PNMTTSHRMAPK1 | |
| SCHEMBL8460159 | 0.73 | IDO1 (0.61) | IDO1TDO2PNMTTSHRMAPK1 | |
| SCHEMBL8464360 | 0.73 | IDO1 (0.61) | IDO1TDO2PNMTTSHRMAPK1 | |
| SCHEMBL8990350 | 0.73 | OPRM1 (0.38) | IDO1TDO2PNMTOPRL1OPRM1 | |
| SCHEMBL4386224 | 0.72 | IDO1 (0.57) | IDO1EPHX1 | |
| SCHEMBL26921796 | 0.72 | OPRL1 (0.54) | IDO1TDO2PNMTOPRL1OPRM1 | |
| SCHEMBL11834096 | 0.72 | IDO1 (0.44) | IDO1TDO2PNMTOPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885TDO2 210/4885PNMT 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.